To Nasdaq Copenhagen A/S                                18 November 2026
                                        Announcement no. 79/2026

Announcement of Drawings

Pursuant to S. 24 of the Capital Markets Act, we hereby publish drawings (repayment) for bonds issued by Jyske Realkredit. Please find the data in the attached file.

The information will also be available on Jyske Realkredit’s web site at jyskerealkredit.com.

For further information about format of data and content of the file we refer to the web site of NASDAQ at www.nasdaqomxnordic.com.

Questions may be addressed to Christian Bech-Ravn, Head of Investor Relations, tel. (+45) 89 89 92 25.

Yours sincerely

Jyske Realkredit

Please observe that the Danish version of this announcement prevails.

www.jyskerealkredit.com

Attachment

WUHU, China, Sept. 18, 2026 (GLOBE NEWSWIRE) — LEPAS is set to launch its first LEPAS Global Elegant Lifestyle Week this October. Since its debut as a new independent brand in 2025, LEPAS has begun its global rollout of products and brand presence, entering the global spotlight.

In 2026, as LEPAS launched its brand and delivered vehicles worldwide, it welcomed its first customers, bringing “Drive Your Elegance” into their everyday lives.

image1

From its first encounters with global media to its first customers, LEPAS is building deeper connections worldwide. As the brand moves from being seen globally to being experienced by customers, LEPAS is creating ongoing opportunities for dialogue and co-creation, listening and responding to diverse market needs. This October, LEPAS will launch its first LEPAS Global Elegant Lifestyle Week under the theme “Together in Elegance.” Users worldwide will participate in brand co-creation and technology experiences, exchange ideas and explore the many meanings of “elegance.”

For LEPAS, the first customers are taking the brand-customer relationship beyond a single purchase and toward an ongoing experience — from one-way communication to active participation. Aesthetic preferences, driving and riding experiences, and vehicle feedback across cultures provide insights into local adaptation and inform LEPAS’s continued refinement of its product portfolio and service quality. By listening and responding, LEPAS is deepening its understanding of user needs and tailoring its products, services and experiences across markets.

image2

Throughout this process, LEPAS remains committed to “elegance” and shaping it with customers. LEPAS engages customers through product experiences, in-person events and co-creation, sharing diverse cultural expressions and perspectives on life while enriching “elegance” through dialogue. Through art, sports and community initiatives, LEPAS also integrates into local life and works with customers across different fields to explore more possibilities for elegant living, with co-creation supporting its continued exploration of global markets.

Building on this foundation, LEPAS will bring together users from different markets at the 2026 Chery International User Summit, giving them an opportunity to exchange ideas and experiences and contribute to the continued development of LEPAS’s products, services and brand. Global communication and user co-creation extend beyond a single event, helping LEPAS maintain connections with users and explore global markets.

In October 2026, the first LEPAS Global Elegant Lifestyle Week will officially begin. The event will showcase LEPAS’s global progress and bring together users, partners and industry guests to explore diverse expressions of “elegance” and contribute to the brand’s future. It will mark a new starting point for LEPAS — from global rollout toward sustained user connections and a new phase of co-creation. Users will move beyond experiencing LEPAS products to become participants and storytellers in the brand’s journey, joining LEPAS as Global Elegant Lifestyle Partners to co-create elegant living.

Building on its progress worldwide, LEPAS looks ahead to a new chapter with its global community. More stories of LEPAS and users shaping elegant lifestyles together are yet to come.

About LEPAS

LEPAS is Chery Auto’s Premium NEV brand, dedicated to creating elegant mobility experiences for users worldwide. Committed to becoming the Preferred Brand for Elegant Mobility Life, LEPAS brings together Leopard Aesthetics, Elegant Technology, and Exquisite Space – transforming elegance into a driving experience you can see, feel, and trust. Supported by a growing global dealer network of more than 500 sales and service outlets, LEPAS is expanding its international footprint through localized operations, delivering products and experiences tailored to users across global markets.

Media Contact

Company Name: LEPAS International

Contact Person: Vincy wang

E-mail: wangxi23@mychery.com

Company Official Website: https://lepasinternational.com/

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/333111b1-651f-4881-8222-55f46ff81ccc

https://www.globenewswire.com/NewsRoom/AttachmentNg/60506020-bc35-472c-a177-f579fdf65196

FORM 8.5 (EPT/RI)

Amendment in 1(b)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Tribal Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor and Joint Broker to Tribal Group Plc
(d)        Date dealing undertaken: 17th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchase

22

81.4 81.4

Ordinary shares

Sales

3,610

81.4 81.4

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 18th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
SThree Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Broker to SThree Plc
(d)        Date dealing undertaken: 17th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchase

461

292.5 289

Ordinary shares

Sales

5,461

292 290

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 18th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

Some of the Largest Names in Finance Choose Dianomi, Including Reuters, CNN Business, Bank of America, Charles Schwab and More

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) — Taboola (Nasdaq: TBLA), a global leader in delivering performance at scale for advertisers, today announced an offer to acquire Dianomi, a leading provider of digital advertising services to premium clients in the business, finance and lifestyle sectors. The acquisition is expected to be completed before the end of 2026, subject to the satisfaction of customary regulatory conditions and approval by Dianomi shareholders.

Dianomi provides premium advertisers, including blue chip names such as Charles Schwab, Invesco and Bank of America, with access to large, high intent audiences via partnerships with hundreds of premium publishers, including Reuters, CNN Business, the Times and WSJ.

Taboola believes that the acquisition of Dianomi will significantly bolster its ability to provide performance advertisers with a highly specialized, premium ad network focused on finance, powered by Taboola’s performance advertising platform Realize. Realize is a technology platform that helps advertisers achieve outcomes at scale, leveraging Taboola’s unique supply, first-party data, and AI. Realize enables performance campaigns across many of the world’s largest publishers.

More than 600 advertisers and publishers trust Dianomi to drive performance in its brand-safe environments. With Dianomi and Taboola together, Taboola believes that advertisers, especially those seeking to reach audiences in the business, finance and lifestyle sectors will have more ways to connect with them to drive performance objectives.

“Dianomi has demonstrated a commitment to connecting the largest financial brands in the world with their target audience to power successful performance-driven advertising,” said Adam Singolda, CEO of Taboola. “Dianomi’s focus on helping advertisers to reach potential consumers within business and finance is a great complement to Taboola’s ability to drive performance within these verticals as well. Together with Dianomi, we will be able to offer an even larger, highly curated, trusted network of publishers that advertisers can tap into to reach audiences, via our Realize performance advertising platform.”

About Taboola
Taboola empowers businesses to grow through performance advertising technology that goes beyond search and social and delivers measurable outcomes at scale.

Taboola works with thousands of businesses who advertise directly on Realize, Taboola’s powerful ad platform, reaching over 600M daily active users across some of the best publishers in the world. Publishers like NBC News and Yahoo, and OEMs such as Samsung, Xiaomi and others use Taboola’s technology to grow audience and revenue, enabling Realize to offer unique data, specialized algorithms, and unmatched scale.

Important information regarding the acquisition
This announcement should be read in conjunction with the transaction announcement released earlier today in accordance with Rule 2.7 of the UK City Code on Takeovers and Mergers, which includes details of the full terms and conditions of the acquisition. A copy will be available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on the investor relations page of Taboola’s website at www.investors.taboola.com. The content of this website is not incorporated into, and does not form part of, this announcement.

This announcement is for information purposes only and is not intended to and does not constitute or form part of, any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the acquisition or otherwise nor shall there be any sale, issuance or transfer of securities of Dianomi in any jurisdiction in contravention of applicable law.

The acquisition will be implemented solely by means of the scheme circular (or if the acquisition is implemented by way of a takeover offer, the offer document), which will contain the full terms and conditions of the acquisition including details of how to vote in respect of the acquisition. Any vote in respect of the scheme (or, if applicable, acceptance of the takeover offer)or other response in relation to the acquisition should be made only on the basis of the information contained in the scheme circular (or, if applicable, the offer document). A transaction implemented by means of a scheme under English law is not subject to the tender offer rules or the proxy solicitation rules under the U.S. Securities Exchange Act of 1934, as amended.

Forward-Looking Statements
Taboola may make certain statements in this press release that are not historical facts and relate to analysis or other information which are based on forecasts or future results. Examples of such forward-looking statements include, but are not limited to, statements regarding the anticipated acquisition of Dianomi; the expected benefits of the acquisition; Taboola’s ability to expand its premium advertising network and publisher relationships, particularly in the business, finance and lifestyle sectors; the ability of Taboola’s Realize platform to connect advertisers with premium supply and drive performance objectives; the anticipated impact of Dianomi’s advertiser, publisher and financial-sector relationships on Taboola’s business; and Taboola’s future prospects, product development, business strategies and growth opportunities.

Words such as “expect,” “estimate,” “project,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” and similar expressions are intended to identify forward-looking statements but are not the exclusive means for identifying such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and there are risks that the predictions, forecasts, projections and other forward-looking statements will not be achieved. You should understand that a number of factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements, including the risks set forth in Taboola’s Annual Report on Form 10-K for the year ended December 31, 2025 under Part I, Item 1A “Risk Factors” and Taboola’s subsequent filings with the Securities and Exchange Commission. Taboola cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Taboola does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

CONTACT: Contact

Press contact
Dave Struzzi
dave.s@taboola.com

Investor contact
Aadam Anwar
aadam.a@taboola.com

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Gooch & Housego plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor and Broker to Gooch & Housego plc
(d)        Date dealing undertaken: 17th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchases

3,561

1202.5 1202.5

Ordinary shares

Sales

3,561

1210 1205

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 18th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Gamma Communications Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Broker to Gamma Communications Plc
(d)        Date dealing undertaken: 17th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchases

296,798

1126 1119

Ordinary shares

Sales

286,798

1126 1118

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION
        
(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 18th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Advanced Medical Solutions Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc
(d)        Date dealing undertaken: 17th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchase

342,142

281.75 281.5

Ordinary shares

Sales

70,097

281.75 281.75

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 18th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

Ipsen appoints Mariette Finet to its Board of Directors

PARIS, FRANCE, 18 SEPTEMBER 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Mariette Finet as a Director to its Board of Directors, effective immediately. Ms. Finet succeeds Ms. Michèle Ollier, who resigned from her position as Director on 1 August 2026.

A Doctor of Medicine and graduate of the University of Nancy, Ms. Finet brings more than 35 years of experience across the healthcare, pharmaceutical and life sciences sectors.

Ms. Finet began her career in the Medical Department of Laboratoires Beaufour in Paris, where she held positions in pharmaceutical asset analysis and conducted clinical research across several therapeutic areas, with a particular focus on gastroenterology. She subsequently joined Beaufour-Ipsen Pharma and later Ipsen, where she held positions in the Marketing Department.

Since 2007, Ms. Finet has served in scientific and medical advisory roles at Mayroy and Highrock S.àr.l., providing expertise in investment analysis and portfolio oversight, with a particular focus on pharmaceutical, MedTech and life sciences sectors. She also served on the boards of Lightinderm SAS and Kaerus Bioscience Ltd.

The Board of Directors has also appointed Ms. Finet to the Board Portfolio Committee, succeeding Ms. Ollier.

Ms. Finet’s appointment will be submitted for ratification at the next Annual Shareholders’ Meeting. Subject to ratification, she will serve for the remainder of Ms. Ollier’s term, which expires at the Annual Shareholders’ Meeting convened to approve the financial statements for the year ending 31 December 2026.

Following this appointment, Ipsen’s Board of Directors continues to comprise 14 directors, with balanced representation of seven women and seven men1. The Board includes four independent directors and two employee representatives.

About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Ipsen Contacts

 

   
Investors    
Henry Wheeler henry.wheeler@ipsen.com +33 7 66 47 11 49
Khalid Deojee khalid.deojee@ipsen.com         +33 6 66 01 95 26
     
Media    
Sally Bain sally.bain@ipsen.com +1 857 320 0517
Anne Liontas anne.liontas.ext@ipsen.com +33 7 67 34 72 96

Disclaimers and/or forward-looking statements

The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com.


1 Representing 42%, with directors representing employees not taken into account in this calculation, pursuant to article L. 225-18-1 of the French Code of Commerce

Attachment

Aktsiaselts Infortar’s subsidiary, AS Tallink Grupp, announced today that the maturity of its loan agreement has been extended by two years. The announcement is available at this link.

Infortar operates in seven countries, the company’s main fields of activity are maritime transport, energy and real estate. Infortar owns a 68.83% shareholding in Tallink Grupp, a 100% share in Elenger Grupp and a versatile and modern real estate portfolio of approx. 141,000 m2. In addition to the three main areas of activity, Infortar also operates in construction and mineral resources, agriculture, and other areas. A total of 107 companies belong to the Infortar group, including 3 associates and 2 subsidiaries of associates. Infortar employs 6890 people.

Additional information:

Kadri Laanvee
Investor Relations Manager
Phone: +372 5156662
e-mail: kadri.laanvee@infortar.ee
www.infortar.ee/en/investor

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.